Article metrics

Download PDFPDF

Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma

 

Online download statistics by month:

Online download statistics by month: December 2019 to March 2024

AbstractFullPdf
Dec 2019010
Jan 2020040
Feb 2020020
Mar 2020020
Apr 2020010
May 2020050
Jun 20200140
Jul 2020051
Aug 2020010
Sep 2020040
Oct 2020041
Nov 2020032
Dec 2020042
Jan 2021051
Feb 2021012
Mar 2021020
Apr 2021030
May 2021042
Jul 2021010
Aug 2021020
Sep 2021021
Oct 2021031
Nov 2021030
Dec 2021061
Jan 2022050
Feb 2022011
Mar 2022010
Apr 2022051
May 2022061
Jun 2022092
Jul 2022042
Aug 2022041
Sep 2022050
Oct 2022030
Nov 2022071
Dec 2022081
Jan 20230123
Feb 2023061
Mar 20230194
Apr 2023019
May 2023040
Jun 2023020
Jul 2023011
Aug 2023020
Sep 2023020
Oct 2023081
Nov 20230111
Dec 20230450
Jan 2024040
Feb 2024090
Mar 2024040
Total027044